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ABSTRACT  
Objectives:  We aimed to assess the prevalence and risk factors for Chagas Disease (CD) in Latin 
American immigrants and to evaluate the accuracy of diagnostic tests. Moreover, we offered to all 
positive subjects a complete free-of-charge clinical/instrumental evaluation as well as benznidazole 
treatment in order to stage the disease and verify drug tolerability.  
Methods: A cross-sectional survey of CD among Latin Americans living in Milan and its 
metropolitan area was conducted between July 2013 and July 2014. Blood samples were tested for 
serologic evidence of CD together with a questionnaire covering demographic and clinical-
epidemiological information.  
Results: Forty-eight (9.6%) of the 501 tested subjects were conclusively diagnosed as having CD. 
The highest prevalence of CD was among those from Bolivia (43/169, 25.4%) and El Salvador 
(4/68, 5.9%). Older age (adjusted odds ratio [aOR] 1.05, p=0.004), a Bolivian origin (aOR 8.80; 
p=0.003), being born in the department of Santa Cruz (aOR 3.72, p=0.047 ), having lived in mud 
houses (aOR 2.68; p=0.019), and having an affected relative (aOR 12.77, p=0.001) were 
independently associated with CD. The ARCHITECT Chagas test showed the highest sensitivity 
(100%) and specificity (99.8%). Twenty-nine of the subjects with CD (60.4%) underwent disease 
staging, ten of whom (35.7%) showed cardiac and/or digestive involvement. Benznidazole 
treatment was associated with high frequency of adverse reactions (19/27, 70.4%) and permanent 
discontinuation (8/27, 29.6%) 
Conclusions CD is highly prevalent among Bolivians and Salvadorans living in Milan. Regions 
with a large Latin American immigrant population should implement programmes of active 
detection and treatment.  
KEY WORDS: Trypanosoma cruzi; screening; Chagas disease; Latin American immigrants; Italy 
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INTRODUCTION  
Chagas disease (CD) or American trypanosomiasis, which is caused by Trypanosoma cruzi, is a 
predominantly vector-borne parasitic zoonosis that, under ecological conditions  is endemic in 
Central and South America, Mexico and Texas [1,2]. However, it can also be transmitted by oral 
route, blood transfusions, organ transplantations, and from mother to child [3], with the last three 
modes of transmission being a matter of concern in non-endemic countries. The World Health 
Organisation (WHO) estimates that about six million people are infected by T. cruzi throughout the 
world, 62% of whom live in countries of the Southern Cone initiative against CD, particularly 
Argentina, Brazil, Bolivia and Mexico [4].  
Over the last 10-15 years, massive migration from Latin America to Europe and the USA has led to 
the urbanisation of CD in non-endemic countries, and a recent meta-analysis of studies of CD 
among Latin Americans living in the European Union (EU) has calculated a pooled prevalence of 
4.2% [5]. Like Spain, Italy hosts many people who have immigrated to the EU but, despite this, the 
disease is largely unknown to Italian physicians, which has led to a call to “break this 
epidemiological silence” [6-9].  
The aims of this study were: 1) to assess the prevalence and risk factors for T. cruzi infection in a 
population of Latin American living in Milan and its metropolitan area; 2) to compare the overall 
accuracy of serological methods to detect T. cruzi infection; 3) to define the clinical stage of the 
disease among infected patients; and 4) to evaluate benznidazole tolerability among treated patients. 
METHODS 
Study design and setting 
This cross-sectional survey of CD was conducted in a population of Latin American (LA) subjects 
living in Milan and its metropolitan area (which hosts the largest LA community in Italy) [10] 
between 30 July 2013 and 30 July 2104. The top 5 countries of origin for this population are Brazil, 
Bolivia, Ecuador, El Salvador and Peru (Fig.1). The participants were recruited by means of an 
active outreach to the local Latino communities with the support of Médecins Sans Frontières 
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(MSF): three MSF health promoters of LA origin participated in 20 health fairs in 13 sites including 
local churches (n= 8) cultural community organizations (n=5) and the Bolivian consolate (n=1). 
Screening sessions took place 2-3 times monthly in a dedicated outpatient clinic at our Hospital and 
at “Opera San Francesco per i  Poveri”,  an outpatient care facility for indigent subjects and 
undocumented immigrants. 
Demographic and clinic-epidemiological information was collected at the time of blood sampling 
using a standardised questionnaire. The study protocol  also included serological testing for  
Strongyloides. Free clinical investigations and treatment were offered to all of the subjects 
diagnosed as having CD.  
The study was approved by the Ethics Committee of AO-Polo Universitario Luigi Sacco, Milan, 
Italy (Protocol No. 480/2013/61/AP) and the Médecins San Frontières Ethics Review Board 
(Geneva, Switzerland). Written informed consent was obtained for subjects before their enrolment 
(in the case of children, this was given by their parents/guardians).  
Laboratory methods 
CD screening was carried using two serological tests in parallel: an enzyme-linked immunosorbent 
assay (ELISA) based on a lysate antigen of T. cruzi (BioELISA Chagas III, BiosChile, Santiago, 
Chile) and a chemiluminescence immunoassay (CLIA) based on recombinant antigens of distinct 
regions of the parasite (ARCHITECT Chagas, Abbott, Chicago, IL, USA), which was performed 
using an automated ARCHITECT i2000SR system (Abbott).  
A subset of blood samples were also tested by means of a CLIA directed against three distinct 
antigenic regions (LIASON XL MUREX Chagas, DiaSorin, Saluggia, Italy) and an 
immunochromatographic test (Trypanosoma cruzi IgG Rapid Test, ImmunoSpark, SD, Rome, Italy) 
in order to investigate their performance in screening CD. Serological testing for anti-Strongyloides 
stercoralis IgG was carried out using the Strongyloides rattii ELISA (Bordier Affinity Products, 
Effegiemme Diagnostici, Milan, Italy).  
CD diagnosis and treatment 
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CD was diagnosed on the basis of the concordant positive results of two independent serological 
tests in accordance with the WHO guidelines [11]. 
Cardiac involvement was investigated by means of  electrocardiography (ECG), chest X-rays, and 
echocardiography. The Brazilian Consensus Classification was used to classify cardiac CD [12]. 
Digestive involvement was assessed by means of a colonic barium enema and a barium X-ray of the 
esophagus and considered pathological as previously reported [13,14].  
All of the CD-positive participants were offered treatment with benznidazole 5 mg/kg/day 
(maximum 300 mg/day) for 60 days. 
Statistical analysis 
The continuous variables were compared using the Mann-Whitney non-parametric test; the 
categorical variables were compared using the chi-squared test, with Fisher’s corrections when 
necessary. Univariate and multivariate logistic regression models were used to identify the factors 
associated with CD. The variables in the multivariate analysis were selected using a backward 
procedure  based on a cut-off p-value of 0.05.   
The diagnostic accuracy of serological test was calculated as sensitivity, specificity, validity index, 
positive and negative predictive values (PPV and NPV), positive and negative likelihood ratio and 
the Youden index, which is a measure of the overall discriminative power of a diagnostic procedure 
and Cohen’s kappa coefficient which describes the level of concordance among tests. 
 
RESULTS 
A total of 501 Latin Americans (63% female) were screened for CD: 471 adults with a median age 
of 39 years (interquartile range [IQR] 32.0-48.7), and  30 children with a median age of 10.5 years 
(IQR 8.2-14.0), of whom seven were born in Latin America and had been adopted by Italians, and 
five were born in Italy of Latin American parents. The median time from their arrival in Italy was 
eight years (IQR 3.5-11.0). Ninety-one percent of the subjects came from four countries (Bolivia, 
Peru , El Salvador, Ecuador); the others came from Brazil (16), Argentina (6), Venezuela (4), Chile 
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(3), Colombia (3), Guatemala (2), Paraguay (2) and Uruguay (1), or had no recorded country of 
origin (8).   
Serology diagnosis 
Initially 46 subjects (9.2%) were diagnosed with T. cruzi infection on the basis of two concordant 
serology results; 451 subjects (90.0%) had negative serology with both tests and 4 (0.8%) had 
initially discordant results: three positive with ARCHITECT (2.87, 4.69 and 1.21 S/CO, 
respectively) and negative with BioELISA (0.03, 0.7 and 0.22 index value, respectively)  and one 
negative with ARCHITECT (0.61 S/CO) and positive with BioELISA (1.2 index value). Repeated 
serology of discordant cases (using also the other available tests) allowed us to resolve the 
discrepancies with two confirmed cases (both with the highest S/CO on ARCHITECT and one of 
whom had a subsequent diagnosis of megacolon) and two negative cases.  
In table 1 are summarised the diagnostic results and performance of serological and 
immunochromatographic assays used for the diagnosis of T. cruzi infection. A high proportion of 
patients were correctly classified by ARCHITECT and BioELISA (validity index 99.80 and 99.40, 
respectively) and both tests showed a high level of agreement (k index 0.955) although the former 
performed better for all measures. The Liaison Chagas assay has a high sensitivity and specificity 
but was slightly less efficient than the counterpart assay employing the chemiluminescence 
detection system. The median S/CO values were 13.8 (IQR 10.6-14.9) for the ARCHITECT assay 
and 11 (IQR 7.6-12) for the Liaison assay. With reference to true positive serum values, 43/48 
samples (89.6%) showed results of > 6S/CO with the ARCHITECT and 25/31 samples (80.6%) 
with the Liaison. 
The performance of the rapid diagnostic test was characterised by low sensitivity (89% and a 
validity index of 91.6% 
Prevalence of CD and risk factors for the disease  
CD was diagnosed in 48 subjects (overall prevalence: 9.6%) of whom 43 coming from Bolivia 
(25.4% of the 169 enrolled Bolivians), four from El Salvador (5.9% of the 68 enrolled 
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Salvadorans), and one from Argentina. Bolivians accounted for 89.6% (43/48) of the subjects with 
CD and only 27.8% (126/453) of those without CD (p<0.0001). Subjects with CD came more 
frequently from the departments of Santa Cruz (24/48, 50% vs 47/453, 10.4%) and Cochabamba 
(15/48, 31.3% vs 43/453, 9.5%; p<0.0001); had more frequently lived in rural areas (39/48, 81.3% 
vs  233/453, 51.4%; p=0.0001) and mud houses (38/48, 79.1% vs  201/453, 44.3%; p<0.0001); were 
more frequently related to people affected by CD  (11/48, 22.9% vs 5/453, 1.1%; p<0.0001 ); and 
were more frequently infected with  S. stercoralis (7/48, 14.6% vs  18/453, 4.%; p=0.001) (Tab. 2). 
Serology for S. stercoralis was positive in 5% of screened individuals (25/501), seventeen of whom 
from Bolivia, 3 from El Salvador, 2 from Peru and 1 from Brazil. Median serology titres were 1.47 
(IQR 1.15-1.95). All patients with CD and strongyloidiasis were from Bolivia. Four out of 14 
patients who underwent culture tested positive for S. stercoralis.  
The results of the multivariate analysis (Tab.3) showed that the factors independently associated 
with an increased risk of developing CD were an older age (aOR: 1.05 for every year older, 95% CI 
1.02-1.09; p=0.004), Bolivian nationality (aOR 8.80, 95% CI 2.10-36.87; p=0.003), being born in 
the department of Santa Cruz (OR 3.72, 95% CI 1.02-13.64; p=0.047), having lived in a mud house 
(OR 2.68, 95% CI 1.17-6.13; p=0.019), and having a relative with a diagnosis of T. cruzi infection 
(OR 12.77, 95% CI 2.96-55.06; p=0.001).  
Staging and treatment of CD cases 
Twenty-nine (60.4%) of the subjects diagnosed with CD underwent clinical evaluations. On the 
basis of the findings of instrumental examinations, 17 subjects (58.6%) were classified as having 
indeterminate CD, four (13.8%) Chagas cardiomiopathy (Cc), five (17.2%) digestive Chagas 
disease, and one Cc + digestive disease (Tab. 4). Only two of these patients were symptomatic: one  
complained  of palpitations and one of constipation. Twenty-seven of the 29 patients accepted 
benznidazole treatment. Nineteen (70.4%) experienced adverse reactions, which led to permanent 
treatment discontinuation in eight cases (29.6%): 4 women (4/19, 21%) and 4 men (4/8, 50%). The 
most frequent side-effects were skin rash (37%), pruritus (18.5%) and fever (14.8%). Two patients 
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had severe polyarthritis (7.4%) requiring hospitalisation, and two complained of severe arthralgias. 
Nervous system disturbances (headache, anxiety, dysgeusia and paresthesia) were recorded in five 
patients (18.5%). 
 
 
DISCUSSION 
This is the first survey of CD among Latin Americans living  in the metropolitan area of Milan 
which hosts the largest community of LA immigrants in Italy. Previous retrospective studies carried 
in Italy have reported CD prevalence rates ranging from 4.2% to 17% [7,9], and  one  cross-
sectional study recorded a prevalence of 7.9% [15]. In line with these data, the prevalence of T. 
cruzi infection in our population as a whole was 9.6%, being much higher (25.6%) among 
Bolivians, a finding that is similar to previous studies carried out in Italy, Spain and Switzerland [7-
9,15-17]. In a meta-analysis by Requena-Méndez et al., the pooled prevalence of T. cruzi infection 
among Bolivians living in Europe was 18.1% [5], which is three times higher than that estimated in 
Bolivia by the WHO (6.1%) [4].  
We found that Bolivian nationality was associated with a 8.8 higher risk of  testing  positive for T. 
cruzi, which may reflect the fact that many of these people came from areas in which T. cruzi is 
hyperendemic [8,9,16,17]. Immigrants from Santa Cruz accounted for 42% of our Bolivian 
population, and being born there was associated with a three times higher risk of developing CD in 
comparison with other Latin American localities outside Bolivia.  
It should also be noted that the prevalence of CD among immigrants from El Salvador was as high 
as 5.9%. According to WHO estimates, El Salvador is fifth most affected Latin American country, 
with a prevalence  of 1.3% [4]. However, two recent studies of pregnant women and blood donors 
living in the departments of Sonsonate and Ahuachapàn found prevalence rates of respectively 3.8% 
and 2.5% [18,19], and it has been reported that the prevalence of CD among Salvadoran immigrants 
living in Los Angeles is 3.4% [20]. There is little information about the prevalence of CD among 
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Salvadorans living in Europe: the above mentioned meta-analysis [5] that included 67 Salvadoran 
migrants found a  pooled prevalence of 3.7%: three times that estimated in El Salvador by the WHO 
[4].  
Our findings also show that, regardless of nationality and department of origin, an older age is 
associated with an increased risk for CD, which probably reflects longer and more intense exposure 
to vector transmission in the country of origin [17] as none of the children in our study had CD. As 
expected, having lived in a mud house and having a relative with CD were also independently 
associated with an increased risk of CD [8,21,22]. The significant higher prevalence of 
strongyloidiasis observed among patients with CD confirms the results of a recent retrospective 
Spanish study highlighting possible shared epidemiologic and socioeconomical risk factors and the 
need of a combined screening for both infections [23].  
CD diagnosis based on simultaneous use of two serological tests is costly and time consuming. 
Moreover, even with this expedient a discordance between  tests can be observed. In our study,  a 
discordance was observed in the 0.8% of cases but this rate was much higher (3.3%) in a recent 
Spanish-Italian study [24]. Repeating the tests on a new serum sample can usually solve much of 
discordant cases but for those with still inconclusive results it is indicated to employ a western 
blotting directed toward trypomastigote excreted-secreted antigens (TESA). On the other hand there 
is increasing need to make serology screening for CD simpler, faster and cheaper possibly using a 
single test. In this regard Abras et al. proposed the use of ARCHITECT Chagas  as a single 
technique for routine screening based on its high sensitivity and specificity [25]. We observed a 
high level of agreement between the two different serological tests employed in our study but we 
confirm that ARCHITECT Chagas had the best performance (100% sensitivity , 99.8% specificity) 
and we concur with the strategy suggested by Abras et al. to reserve a second test only for positive 
sera with a result < 6 S/CO  that in our study were about 10% [25]. 
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Previous studies have shown that the sensitivity of rapid diagnostic tests is unacceptable for 
screening purposes [26,27], and our own experience with the ImmunoSpark assay  resulted 
unsatisfactory (validity index  91.6%).  
More than one-third of our patients with CD showed organ involvement, with  digestive disease 
being the most frequent (17.2%). This is consistent with the findings of two Italian studies [8,9], 
and  suggests that digestive CD may be more frequent in Italy than in Spain or Switzerland 
[17,21,22,28]. This may be due to differences in the origins of the study populations and the disease 
classification criteria (inclusion of dolichocolon) [8], which may lead to the over-diagnosis of 
digestive CD [29]. However, even excluding  people with dolichocolon, the 10.3% frequency of 
megacolon in almost all of our asymptomatic subjects is  higher than that reported in other studies 
of patients complaining of digestive symptoms [17,21], thus supporting the importance of 
radiographic evaluation  of all patients testing positive for CD. Conversely, we did not detect any 
abnormalities in the esophagus X-ray in our asymptomatic subjects, which argues against the 
usefulness of systematic esophageal assessments suggested by some authors [8,21].  
The efficacy of benznidazole in the treatment of chronic CD is still debated, particularly its ability 
to slow the progression of Chagas cardiomyopathy [30,31]. A considerable proportion (70%) of our 
patients experienced adverse drug reactions (mainly skin rash) and about one-third permanently 
discontinued treatment a rate similar to that observed in  studies carried out in non-endemic 
countries, but higher than that reported in endemic countries [31-34]. It remains to be established 
whether this reflects European physicians’ lack of confidence and experience in treating CD, or 
other  reasons such as the gender composition of the study population [33]. 
We acknowledge that our study has several limitations. Firstly, individuals who came to make the 
screening may be not representative of the whole population of LA immigrants living in our 
metropolitan area  and might have been more motivated by perceving themselves at risk of CD and 
thus our results can overestimate the true prevalence of the infection, a selection bias observed also 
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in other studies conducted in Europe [5,35]. Secondly, our results may not be generalizable to other 
European countries or Italian regions. 
In conclusion, CD is highly prevalent among Bolivians and Salvadorans and therefore regions with 
large LA immigrant communities, such as ours, should implement programmes aimed at actively 
detecting and treating CD with particular attention to special population such as pregnant women 
and immunocompromised patients.  
 
Figure legend 
Figure 1. Countries of origin and number of people living in Milan and its metropolitan area 
(overall) in 2014 for the five more represented communities of Latin American immigrants (Ref.10) 
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Table 1.  Performance of four serological tests for the diagnosis of T.cruzi infection a. 
 
Measure ARCHITECT Chagas b 
(n=501) 
 BioELISA Chagas III c 
(n=501) 
 Chagas Liaison XL d 
(n=263) 
 Chagas Rapid ImmunoSpark e 
(n=95) 
 Number/total 95% CI  Number/total 95% CI  Number/total 95% CI  Number/total 95% CI 
Sensitivity (%) 100 (49/49) 91.01-100  95.92 (47/49) 85.34-99.56  96.77 (30/31) 82.15-100  89.29 (25/28) 71.79-96.96 
Specificity (%) 99.78 (451/452) 98.60-100  99.78 (451/452) 98.60-100  99.14 (230/232) 96.66-99.95  92.54 (62/67) 83.21-97.08 
Validity index (%) 99.80 (500/501) 99.41-100  99.40 (498/501) 98.73-100  98.86 (260/263) 97.58-100  91.58 (87/95) 85.99-97.16 
PPV (%) 98.00 (49/50) 94.12-100  97.92 (47/48) 93.88-100  93.75 (30/32) 85.36-100  83.33 (25/30) 70.00-96.67 
NPV (%) 100 (451/451) 100-100  99.56 (451/453) 98.95-100  99.57 (230/231) 98.72-100  95.38 (62/65) 90.28-100 
LR+ 452.00  63.81-3201.83  433.55 61.15-3073.76  112.26 28.20-446.85  11.96 5.10-28.07 
LR- 0.00 -  0.04 0.01-0.16  0.03 0.00-0.22  0.12 0.04-0.34 
Youden’s index 1.00 1.00-1.00  0.96 0.86-1.00  0.96 0.83-1.00  0.82 0.65-0.92 
 
a- In case of discordant results serology was repeated using a new sample after 2-4 months. 
b- The chemiluminescent reaction is measured in relative light units (RLUs). The results are expressed as sample RLUs/cutoff value (S/CO) with ratio < 0.8 
considered negative, inconclusive from ≥ 0.8 to < 1 and ≥ 1 positive. 
c- For the ELISA test results were expressed as the index between the absorbance of the test serum and the cutoff value. Tests were considered negative if the index 
was < 0.9, equivocal if ≥ 0.9 and < 1, and positive if ≥1. 
d- The chemiluminescent reaction is measured in relative light units (RLUs). The results are expressed as sample RLUs/cutoff value (S/CO) with ratio < 0.9 
considered negative, inconclusive from ≥ 0.9 < 1 and ≥  1 positive. 
e - 5 µL of serum were added in the sample port following the transfer of 2 full drops of conjugate into the reagent port. The results were read within 5 minutes after 
the sample application. The test was considered positive if a pink/purple line was seen in the test and control areas. The test was considered negative if a pink/purple 
line was seen only in the control area. The test was invalid (and was repeated) if the control line failed to appear. 
 
PPV: positive predictive value; NPV: negative predictive value; LR+: positive likelihood ratio; LR-: negative likelihood ratio.95%CI, 95% confidence interval.  
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Table 2. Characteristics of the participants who were positive and  negative to T. cruzii screening. 
 
 
Variable 
 
Total screened 
N=501 
 
Negative   
for CD 
(n=453) 
 
Positive 
 for CD 
(n=48) 
 
 
P value 
Age in years, median (IQR)  39 (31-48) 39 (31-48) 41 (17-66) 0.405 
Females 
Males 
315 (62.9) 
186 (37.1) 
283 (62.5) 
170 (37.5) 
16  (33.3) 
32  (66.7) 
0.448 
Country of origin, n (%) 
   Bolivia 
   Peru 
   El Salvador 
   Ecuador 
   Other 
 
169 (33.7) 
159 (31.8) 
68 (13.6) 
60 (12.0) 
45 (9.0) 
 
126 (27.8) 
159 (35.1) 
64  (14.1) 
60  (13.2) 
44  (  9.7) 
 
43  (89.6) 
0  (0.0) 
4  ( 8.3) 
0  (0.0) 
1  (2.1) 
 
<0.0001 
Department of origin, n (%) 
   Santa Cruz 
   Cochabamba 
   La Paz 
   Other 
 
71  (14.2) 
58  (11.6) 
18  (  3.6) 
354 (70.7) 
 
47   (10.4) 
43   (9.5) 
18   (4.0) 
345 (76.2) 
 
24 (50.0) 
15 (31.3) 
0   (0.0) 
9  ( 18.7) 
 
<0.0001 
Had lived in rural areas, n (%) 
   Yes 
   No 
 
272 (54.2) 
229 (45.7) 
 
233 (51.4) 
220 (48.6) 
 
39 (81.2) 
9 (18.7) 
 
0.0001 
Had lived in mud houses, n (%) 
  Yes 
  No 
 
239 (47.7) 
262 (52.3) 
 
201 (44.3) 
252 (55.7) 
 
38(79.2) 
10 (20.8) 
 
<0.0001 
Had received transfusion,  n (%) 
   Yes 
   No 
 
43 (8.6) 
458 (91.4) 
 
3 (6.3) 
45 (93.7) 
 
40    (8.8) 
413 (91.2) 
 
0.569 
Had a relative with CD, n (%) 
Yes 
No 
 
16  (3.2) 
485 (96.8) 
 
5 (1.1) 
448 (98.9) 
 
11 (22.9) 
37 (77.1) 
 
<0.0001 
Positive to Strongyloides serology, n (%) 
Yes 
No 
 
25 (5.0) 
476 (95.0) 
 
18 (4.0) 
435 (96.0) 
 
7 (14.6) 
41 (85.4) 
0.001 
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Table 3- Univariate and multivariate logistic regression analysis of the risk factors for Chagas disease  
 
 Univariate analysis              Multivariate analysis 
 OR 95% CI p value  aOR 95% CI P value 
Age, for 1 year  more 1.01 0.99-1.04 0.314  1.05 1.02-1.09 0.004 
Gender 
   Males 
   Females 
 
1 
1.28 
 
 
0.67-2.44 
 
 
0.449 
  
 
- 
 
 
- 
 
 
- 
Country of origin 
  All but Bolivia 
  Bolivia 
 
1 
21.80 
 
 
8.43-56.35 
 
 
<0.0001 
  
1 
8.80 
 
 
2.10-36.87 
 
 
0.003 
Department of origin 
   Provinces outside Bolivia 
   Santa Cruz 
   Cochabamba 
   La Paz 
 
1 
17.99 
12.96 
0.98 
 
 
7.96-40.66 
5.42-30.96 
0.05-18.92 
 
 
<0.0001 
<0.0001 
0.991 
  
1 
3.72 
2.09 
0.18 
 
 
1.02-13.64 
0.56-7.78 
0.01-4.06 
 
 
0.047 
0.272 
0.278 
Having  lived in rural areas  
 No  
  Yes 
 
1 
3.99 
 
 
1.88-8.44 
 
 
<0.001 
  
 
- 
 
 
- 
 
 
- 
Having lived in mud houses 
No  
Yes 
 
1 
4.64 
 
 
2.25-9.56 
 
 
<0.0001 
  
1 
2.68 
 
 
1.17-6.13 
 
 
0.019 
Previous transfusions  
  No  
  Yes 
 
1 
0.70 
 
 
0.21-2.37 
 
 
0.571 
  
 
- 
 
 
- 
 
 
- 
Having a relative with CD 
No  
Yes 
 
1 
24.22 
 
 
7.86-74.57 
 
 
<0.0001 
  
1 
12.77 
 
 
2.96-55.06 
 
 
0.001 
Serological positivity for Strongyloides  
No  
Yes 
 
1 
4.23 
 
 
 
1.67-10.73 
 
 
0.002 
  
1 
12.77 
 
- 
 
 
- 
 
The strength of the associations was measured by means of odds ratios (ORs) and adjusted ORs (aORs) with their 95% confidence intervals (95% CI). All of the 
data were statistically analysed using SAS version 9.4, and differences with p-values of <0.05 were considered statistically significant.
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Table 4- Clinical characteristics of 29 subjects with Chagas disease who underwent clinical 
staging. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*RBBB: right bundle branch block; §IRBB: incomplete right bundle-branch block; ‡ Confirmed to be 
sarcoidosis 
Characteristic N (%) 
Country of origin 
Bolivia 
El Salvador 
Argentina 
 
26 (89.7) 
 2 (6.9) 
 1 (3.4) 
Median age (IQR) 37.5 (17-67) 
Gender 
Male 
Female 
 
7 (24.1) 
22 (75.9) 
Clinical stage,  
 
Indeterminate 
Chagas cardiomyopathy 
Digestive Chagas  
Chagas cardiomyopathy + digestive disease  
18 (62.1) 
  4 (14.3) 
  5 (17.8) 
  1 (3.6) 
ECG,  
Normal 
RBBB*  
Right focal BBB 
Sinus bradycardia (< 50 bpm) 
Sinus bradycardia+RBBB 
IRBB§ 
 
22 (75.9) 
  2  (6.9) 
  1  (3.4) 
  2  (6.9) 
  1  (3.4) 
  1  (3.4) 
Chest radiography  
Normal 
Enlarged heart  
Hylar lymphadenopathy‡ 
 
27 (93.1) 
1  (3.5) 
1  (3.5) 
Echocardiography  
Normal ejection fraction (>50%) 
Normal findings 
Mild tricuspid regurgitation 
Mild mitral regurgitation 
Mild mitral and aortic regurgitation 
Tricuspid insufficiency 
 
29 (100) 
12 (41.4) 
 7  (20.7) 
 5  (17.2) 
 1  ( 3.4) 
 2  (6.9) 
Esophageal barium  
Normal 
 
29 (100) 
Barium enema  
Normal 
Dolichocolon 
Megacolon 
 
22 (75.0) 
 4 (14.3) 
 3 (10.7) 
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